Literature DB >> 23151733

An integrative approach for evaluating work related musculoskeletal disorders.

Wricha Mishra1, De Amitabha, R Iqbal, S Gangopadhyay, A M Chandra.   

Abstract

OBJECTIVES: To develop a framework for evaluating the work related musculoskeletal disorders (WRMSDs). PARTICIPANTS: The proposed framework was tested on 15~jewellery manufacturing workers working at Chinchpokhli region in Mumbai, India and on 15 students studying in a management institute of Mumbai, India.
METHODS: The framework has been broken into three phases. Phase 1--Ergonomic-risk evaluation; Phase 2--Musculoskeletal Disorders (MSD) evaluation and Phase 3--Clinical examination. Ergonomic-risk evaluation determines the relationship between work relatedness and musculoskeletal disorders. Musculoskeletal Disorders (MSD) evaluation tries to assess the presence of discomforts/disabilities in different body regions, through subjective evaluation tools. Ergonomic-risk evaluation involved QEC, PLIBEL and posture analysis by RULA. Musculoskeletal Disorders (MSD) evaluation involved administration of self reported questionnaires. Clinical examination involved muscle grading by a physiotherapist and back strength measurement.
RESULTS: The framework suggested that ergonomic risk evaluation techniques, self reported body part questionnaires and physical measurement of physiological/biomechanical transients may have a relationship and can be used for the evaluation of work related musculoskeletal disorders.
CONCLUSION: The proposed integrative approach will help in developing stage wise intervention strategies for work related musculoskeletal disorders.

Entities:  

Mesh:

Year:  2012        PMID: 23151733     DOI: 10.3233/WOR-2012-1460

Source DB:  PubMed          Journal:  Work        ISSN: 1051-9815


  1 in total

1.  Assessing the effects of an educational program for the prevention of work-related musculoskeletal disorders among school teachers.

Authors:  Jian Shuai; Pengying Yue; Liping Li; Fengying Liu; Sheng Wang
Journal:  BMC Public Health       Date:  2014-11-24       Impact factor: 3.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.